Lindsey Shapiro, PhD, science writer —

The U.S. Food and Drug Administration (FDA) has granted conditional approval to Pfizer‘s elranatamab — an antibody therapy to be marketed under the brand name Elrexfio — for adults with difficult-to-treat multiple myeloma. Eligible patients will have received at least four prior lines of therapy, including a…

A European Medicines Agency committee has recommended that one antibody-based cancer therapy from Janssen Pharmaceuticals be approved for the treatment of relapsed and refractory multiple myeloma (RRMM), and that a second — one already with approval in the European Union for RRMM — be cleared for a less-frequent…

The International Myeloma Foundation (IMF) will host its second in-person Patient and Family Seminar of the year on Aug. 18-19 in Los Angeles. At the upcoming event, which will be held at the Sofitel Hotel in the Southern California city and livestreamed, individuals with this rare cancer…

Janssen is asking the U.S. Food and Drug Administration (FDA) to expand approval its cell therapy Carvykti (ciltacabtagene autoleucel) to allow for earlier treatment of people with relapsed or refractory multiple myeloma (RRMM). Carvykti is approved in the U.S. for people with heavily treated myeloma, or…

ISB 1442, Ichnos Sciences’ investigational bi-specific antibody-based treatment, has earned orphan drug designation from the U.S. Food and Drug Administration (FDA) for treating relapsed or refractory multiple myeloma. The designation is awarded to therapies that show promise for rare diseases, those affecting fewer than 200,000 people in the U.S.

Multiple myeloma patients in the U.S. will now have access to Rapid Novor‘s noninvasive and highly sensitive blood test for monitoring minimal residual disease activity, or the small number of cancer cells that remain in a patient’s body after treatment. The test, called EasyM, previously was…

The U.S. Food and Drug Administration (FDA) has granted fast track and regenerative medicine advanced therapy designations to CT103A, IASO Biotherapeutics’ experimental CAR T-cell therapy for relapsed or refractory multiple myeloma (RRMM), the company announced. These statuses complement the orphan drug designation the treatment received from the regulatory…

Extremes in body mass index (BMI) — a ratio of weight to height that’s used to estimate a person’s healthy weight — are associated with a worse prognosis among people with multiple myeloma, according to data from more than 1,000 patients. Specifically, underweight and severely obese patients experienced a…

In people with newly diagnosed multiple myeloma following a stem cell transplant, a triple-combination maintenance therapy — of Revlimid (lenalidomide), Kyprolis (carfilzomib) and dexamethasone — significantly extended the time to disease progression or death, by 49%, compared with Revlimid alone. That’s according to an interim analysis of…

A new investigational CAR T-cell therapy, called MCARH109, demonstrated an ability to shrink or eliminate the amount of cancer in patients with relapsed or refractory multiple myeloma, according to results from a dose-escalation Phase 1 trial. Safety findings showed the treatment at its highest dose was not safe for…